4,699 Shares in Astrazeneca Plc $AZN Purchased by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft acquired a new position in Astrazeneca Plc (NYSE:AZN) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 4,699 shares of the company’s stock, valued at approximately $920,000.

Several other large investors have also modified their holdings of the business. IHT Wealth Management LLC raised its holdings in shares of Astrazeneca by 0.3% in the fourth quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock worth $3,076,000 after buying an additional 54 shares during the period. Visionary Wealth Advisors boosted its holdings in Astrazeneca by 1.5% during the 4th quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock valued at $737,000 after acquiring an additional 60 shares during the period. Vista Investment Management boosted its holdings in Astrazeneca by 0.3% during the 4th quarter. Vista Investment Management now owns 21,215 shares of the company’s stock valued at $3,723,000 after acquiring an additional 60 shares during the period. Kestra Investment Management LLC grew its position in Astrazeneca by 1.9% in the 4th quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock valued at $595,000 after acquiring an additional 63 shares during the last quarter. Finally, Luken Investment Analytics LLC increased its stake in Astrazeneca by 4.3% in the fourth quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock worth $274,000 after purchasing an additional 64 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Astrazeneca Price Performance

AZN opened at $164.14 on Tuesday. Astrazeneca Plc has a 12-month low of $137.23 and a 12-month high of $212.71. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The business’s fifty day simple moving average is $181.80 and its 200-day simple moving average is $188.30. The company has a market capitalization of $254.56 billion, a price-to-earnings ratio of 24.65, a PEG ratio of 1.38 and a beta of 0.24.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The firm had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. On average, equities research analysts anticipate that Astrazeneca Plc will post 10.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AZN has been the subject of several research analyst reports. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Barclays restated a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. HSBC lowered shares of Astrazeneca from a “buy” rating to a “hold” rating in a report on Monday, July 13th. Finally, UBS Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $211.00.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.